Teva Pharmaceuticals licenses migraine treatment candidates

  Teva Pharmaceutical Industries Ltd. and UK-based Heptares Therapeutics, a subsidiary of Tokyo-based Sosei Group have announced a licensing of its migraine treatment candidates. Under the agreement More...